 |
| |
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Sector Perform |
$17 |
|
| Jul-10-17 | Reiterated |
H.C. Wainwright |
Buy |
$25 → $24 |
|
| Apr-27-17 | Reiterated |
Needham |
Buy |
$14 → $18 |
|
| Apr-27-17 | Reiterated |
H.C. Wainwright |
Buy |
$18 → $21 |
|
| Dec-27-16 | Reiterated |
H.C. Wainwright |
Buy |
$17 → $18 |
|
| Dec-20-16 | Reiterated |
JMP Securities |
Mkt Outperform |
$16 → $19 |
|
| Nov-15-16 | Initiated |
Aegis Capital |
Buy |
|
|
| Sep-29-16 | Initiated |
Brean Capital |
Buy |
|
|
| Mar-16-16 | Reiterated |
Needham |
Buy |
$18 → $14 |
|
| Jan-21-16 | Initiated |
Credit Suisse |
Neutral |
|
|
| Dec-15-15 | Reiterated |
Needham |
Buy |
$14 → $18 |
|
| Dec-15-15 | Reiterated |
H.C. Wainwright |
Buy |
$24 → $25 |
|
| Dec-07-15 | Initiated |
H.C. Wainwright |
Buy |
$24 |
|
| Sep-09-15 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Aug-13-15 | Initiated |
Morgan Stanley |
Equal-Weight |
$10 |
|
| Jun-22-15 | Initiated |
JMP Securities |
Mkt Outperform |
$24 |
|
| May-14-15 | Initiated |
Brean Capital |
Buy |
$18 |
|
| May-11-15 | Initiated |
Needham |
Buy |
$14 |
|
| Apr-14-14 | Initiated |
UBS |
Buy |
$28 |
|
|
|
| Sep-22-17 05:33PM | Ex-Akebia employee suspected of insider trading re-arrested Reuters |
| 05:27PM | Ex-Akebia employee suspected of insider trading re-arrested Reuters |
| Sep-08-17 08:35AM | Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
| Sep-07-17 01:24PM | BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks |
| Sep-05-17 08:42AM | Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge Zacks |
| 08:30AM | Akebia to Present at Upcoming Investor Conferences Business Wire |
| Aug-23-17 07:10AM | Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program ACCESSWIRE |
| Aug-14-17 08:27AM | Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017 Capital Cube |
| Aug-08-17 11:04PM | Akebia Therapeutics reports 2Q loss Associated Press |
| 04:05PM | Akebia Announces Second Quarter 2017 Financial Results Business Wire |
| Aug-04-17 04:05PM | Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
| Jul-24-17 01:53PM | ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017 Capital Cube |
| Jul-20-17 05:08PM | Ex-Akebia employee faces losing bail in insider trading case Reuters |
| Jul-14-17 12:41PM | ETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017 Capital Cube |
| Jul-12-17 03:09PM | Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : July 12, 2017 Capital Cube |
| Jul-11-17 09:15AM | Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017 Capital Cube |
| Jul-06-17 07:00AM | Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Business Wire |
| Jun-29-17 09:26AM | Biotech Movers: Akebia Shares Down After Pricing Stock Offering TheStreet.com |
| Jun-28-17 10:46PM | Akebia Announces Pricing of Public Offering of Common Stock Business Wire |
| 04:15PM | Akebia Therapeutics Announces Proposed Public Offering of Common Stock Business Wire |
| Jun-20-17 07:00AM | Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017 Business Wire |
| Jun-05-17 08:00AM | Akebia Prevails in Two Additional European Patent Disputes Business Wire |
| May-25-17 08:30AM | Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer Business Wire |
| May-24-17 07:00AM | Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents Business Wire |
| May-17-17 06:59PM | Four Stocks Moving On Both News And The Charts Forbes |
| 08:00AM | Today's Research Reports on Stocks to Watch: Akebia Therapeutics and xG Technology Accesswire |
| May-16-17 12:02PM | Why Akebia Therapeutics Stock Is Skyrocketing Today Motley Fool +16.36% |
| 09:34AM | Biotech Movers: Akebia, Editas, Novavax TheStreet.com |
| 01:01AM | Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval GlobeNewswire |
| May-15-17 04:05PM | Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact TheStreet.com |
| 04:05PM | Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval Business Wire |
| May-09-17 06:28PM | Akebia Therapeutics reports 1Q loss Associated Press |
| 04:05PM | Akebia Announces First Quarter 2017 Financial Results Business Wire |
| May-04-17 04:05PM | Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
| Apr-28-17 04:34PM | Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : April 28, 2017 Capital Cube |
| 08:20AM | Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8% Zacks |
| Apr-27-17 12:05PM | 4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma Benzinga +5.84% |
| 08:33AM | Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : April 27, 2017 Capital Cube |
| Apr-26-17 05:45PM | Why Akebia Therapeutics Shares Soared 33.4% Today Motley Fool +33.40% |
| 10:59AM | Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy TheStreet.com |
| 09:27AM | Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka TheStreet.com |
| Apr-25-17 07:00PM | Akebia expands anemia drug pact with Japanese firm, lifting shares American City Business Journals |
| 05:41PM | Akebia shares jump on expanded anemia drug deal with Otsuka MarketWatch |
| 04:25PM | Akebia Expands Anemia Pill Partnership to Include Europe, China Rights TheStreet.com |
| 04:05PM | Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories Business Wire |
| 04:01PM | Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories Business Wire |
| Apr-07-17 07:30AM | Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
| Mar-29-17 04:05PM | Akebia to Present at the 16th Annual Needham Healthcare Conference Business Wire |
| Mar-28-17 07:00AM | Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease Business Wire |
| Mar-10-17 01:04PM | AKEBIA THERAPEUTICS, INC. Financials |
| Mar-07-17 02:34PM | Why Akebia Therapeutics Inc. Tanked Today Motley Fool -12.78% |
| 02:34PM | Why Akebia Therapeutics Inc. Tanked Today at Motley Fool |
| 09:28AM | Biotech Premarket Movers: Innoviva, Akebia, Geron |
| Mar-06-17 11:34PM | Edited Transcript of AKBA earnings conference call or presentation 6-Mar-17 9:30pm GMT Thomson Reuters StreetEvents |
| 05:54PM | Akebia Therapeutics reports 4Q loss Associated Press |
| 04:08PM | AKEBIA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report |
| 04:05PM | Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results Business Wire |
| 07:07AM | Q4 2016 Akebia Therapeutics Inc Earnings Release - After Market Close |
| Mar-01-17 08:30AM | Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights Business Wire |
| Feb-22-17 03:53PM | 3 Biotech Stocks You May Be Overlooking Motley Fool |
| 03:53PM | 3 Biotech Stocks You May Be Overlooking at Motley Fool |
| Feb-15-17 08:40AM | KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6% Zacks |
| Feb-14-17 09:30AM | The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics Zacks |
| Feb-13-17 09:14AM | Forget Gilead, Buy These 5 Biotech Stocks Instead |
| 08:15AM | Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4% |
| 07:07AM | AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ |
| 07:00AM | Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation Business Wire |
| Feb-08-17 12:10PM | Merrimack Pharmaceuticals employee arrested, charged with insider trading at bizjournals.com |
| Feb-03-17 08:30AM | Concordia International (CXRX) Looks Good: Stock Jumps 11.4% |
| 08:30AM | Akebia to Present at the 19th BIO CEO & Investor Conference Business Wire |
| Jan-18-17 08:31AM | Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge |
| Jan-11-17 10:51AM | Moving Average Crossover Alert: Akebia (AKBA) |
| Jan-05-17 12:56PM | Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc. at Motley Fool |
| Jan-03-17 08:35AM | Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session |
| Jan-01-17 03:07PM | 3 Under-the-Radar Biotech Stocks to Watch in 2017 at Motley Fool |
| Dec-30-16 08:44AM | Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy? |
| Dec-29-16 04:24AM | Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue? |
| Dec-28-16 10:08AM | Top Ranked Momentum Stocks to Buy for December 28th |
| Dec-22-16 07:21AM | Christmas Came Early for These Biotech Stocks at Motley Fool |
| Dec-21-16 01:28PM | Akebia Therapeutics Inc (AKBA) Sells Partial US Rights For Vadadustat To Otsuka at Insider Monkey |
| 08:45AM | Akebia Therapeutics (AKBA) in Focus: Stock Jumps 19.4% |
| Dec-20-16 02:19PM | Why Akebia Therapeutics Inc Stock Zoomed Higher Today at Motley Fool +19.40% |
| 11:35AM | Akebia Therapeutics Jumps on License and Collaboration Deal |
| 07:06AM | AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement |
| 07:01AM | Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights |
| 07:00AM | Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S. Business Wire |
| Dec-17-16 04:27PM | Is Akebia Therapeutics Inc (AKBA) A Good Stock To Buy? at Insider Monkey |
| Dec-14-16 04:07PM | AKEBIA THERAPEUTICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers |
| Dec-12-16 07:00AM | Akebia Prevails in Additional European Patent Dispute Business Wire |
| Dec-07-16 07:07AM | SHAREHOLDER ALERT: Sarraf Gentile LLP Announces Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. Marketwired |
| Dec-02-16 04:05PM | Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
| Nov-28-16 02:28PM | Akebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 |
| Nov-15-16 07:43AM | Coverage initiated on Akebia Therapeutics by Aegis Capital |
| Nov-09-16 04:05PM | AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +10.64% |
| 04:04PM | Akebia Therapeutics reports 3Q loss |
| 04:01PM | Akebia Announces Third Quarter 2016 Financial Results Business Wire |
| Oct-31-16 04:05PM | Akebia to Present at the Credit Suisse 25th Annual Healthcare Conference Business Wire |
| Oct-17-16 07:00AM | Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2016 Annual Meeting Business Wire |
| Sep-29-16 09:05AM | Akebia Price Target Lowered, Still A Buy At Brean |
| Sep-26-16 07:00AM | Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia Business Wire |
|
|
|
|
| Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Dahan Michel | SVP, Chief Business Officer | Aug 15 | Sale | 15.00 | 5,000 | 75,000 | 102,224 | Aug 17 04:06 PM | | Satter Muneer A | Director | Jul 05 | Buy | 14.50 | 1,034,482 | 14,999,989 | 3,037,042 | Jul 11 04:14 PM | | Hadas Nicole R. | SVP, General Counsel, Sec. | Jul 03 | Sale | 14.26 | 1,554 | 22,156 | 109,607 | Jul 06 12:24 PM | | Dahan Michel | SVP, Chief Business Officer | Jul 03 | Sale | 14.26 | 1,399 | 19,947 | 107,224 | Jul 06 12:25 PM | | Nash Duane | Director | Jul 03 | Sale | 14.27 | 990 | 14,127 | 23,687 | Jul 06 12:23 PM | | Hadas Nicole R. | SVP, General Counsel, Sec. | Apr 03 | Sale | 9.18 | 1,556 | 14,280 | 109,856 | Apr 04 04:01 PM | | Nash Duane | Director | Apr 03 | Sale | 9.20 | 991 | 9,119 | 24,677 | Apr 04 04:01 PM | | Dahan Michel | SVP, Chief Business Officer | Apr 03 | Sale | 9.18 | 1,401 | 12,858 | 108,623 | Apr 04 04:01 PM | | Butler John P. | CEO and President | Jan 19 | Option Exercise | 0.47 | 20,000 | 9,400 | 373,480 | Jan 23 04:10 PM | | Nash Duane | Director | Jan 03 | Sale | 10.46 | 1,980 | 20,711 | 25,668 | Jan 03 04:02 PM | | Dahan Michel | SVP, Chief Business Officer | Jan 01 | Sale | 10.49 | 1,629 | 17,089 | 70,524 | Jan 03 04:02 PM | | Hadas Nicole R. | SVP, General Counsel, Sec. | Jan 01 | Sale | 10.49 | 1,810 | 18,988 | 82,912 | Jan 03 04:01 PM | | Nash Duane | Director | Oct 03 | Sale | 8.96 | 1,981 | 17,746 | 27,648 | Oct 04 04:12 PM | | Hadas Nicole R. | SVP, General Counsel, Sec. | Oct 01 | Sale | 8.95 | 1,556 | 13,934 | 83,915 | Oct 04 04:12 PM | | Dahan Michel | SVP, Chief Business Officer | Oct 01 | Sale | 8.95 | 1,401 | 12,546 | 72,153 | Oct 04 04:12 PM |
|
|
|
|
|
|
